ABL, Inc. Announces Hiring of Marykay Marchigiani As Chief Financial Officer
June 4, 2018 (Rockville, MD) – ABL, Inc. (ABL) a leading global contract research and manufacturing service provider to the biopharmaceutical industry announces the hire of Marykay Marchigiani as Chief Financial Officer (CFO). As CFO, Ms. Marchigiani will report to the Chief Executive Officer (CEO) and will head the Finance, Accounting and Contracts departments. Most recently, Ms. Marchigiani served as CFO at Battelle National Biodefense Institute, leading the corporate strategy for business operations of the National Biodefense Analysis and Countermeasures Center (NBACC) supporting the Federal Bureau of Investigation in bioforensic analysis of evidence from bio-crime or terrorist attacks, and the Department of Homeland Security in research and development to better understand biological threats and countermeasures. Prior to this, she served in the roles of CFO of Censeo Consulting Group, the Director of Government Accounting at Medimmune LLC, and Vice President and Sector Controller at Science Applications International Corporation. Marykay graduated from Virginia Polytechnic Institute and State University with a Bachelor’s of Science degree in Finance, and she is a Certified Public Accountant.
“I am very excited to join the leadership team of ABL,” said Ms. Marchigiani. “I look forward to contributing to the strategic direction of this dynamic firm that is poised for substantial growth.”
Dr. Thomas VanCott, President and CEO of ABL stated, “Marykay’s depth of experience leading financial operations for highly technical and scientific organizations will prove invaluable as ABL continues to expand its business. I look forward to working with her to further improve our operations and ultimately to provide better results for our clients.”
About ABL, Inc.
ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing therapeutics, vaccines and other biologic products. ABL has extensive experience working with diverse organizations including industry, government and academic entities. ABL maintains GMP facilities meeting U.S. and European regulatory standards, providing process and assay development, cGMP manufacturing of bulk drug substance, cGMP aseptic fill and finish of drug product, and QC bioanalytical testing. Our U.S. and European immunological and molecular laboratories support clients’ preclinical and GCLP clinical sample processing and testing needs. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally.
Latest posts by Chris Frew (see all)
- CRB Announces Matthew Khair Named a Senior Associate Design Services Group - April 22, 2019
- Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder - April 18, 2019
- REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer - April 17, 2019